|
CN112047931A
|
|
FXIa coagulation factor inhibitor, and pharmaceutical composition and application thereof
|
|
CN111349557A
|
|
Biological incubator
|
|
CN111793064A
|
|
Compound as IRAK inhibitor and preparation method and application thereof
|
|
CN111560012A
|
|
Compound as IRAK inhibitor
|
|
CN111499612A
|
|
Compound as IRAK inhibitor and preparation method and application thereof
|
|
CN112010774A
|
|
FXIa coagulation factor inhibitor, and pharmaceutical composition and application thereof
|
|
CN111763171A
|
|
FXIa coagulation factor inhibitor, and pharmaceutical composition, preparation method and medical application thereof
|
|
CN112292376A
|
|
Quaternary lactam compound and pharmaceutical application thereof
|
|
CN111362920A
|
|
Compound as IRAK inhibitor
|
|
CN110343089A
|
|
Benzimidazole derivative and pharmaceutical use thereof
|
|
CN109897028A
|
|
Dabigatran ester derivant and its pharmaceutical use
|
|
CN109125274A
|
|
Medicinal acid composition of injection benzimidazole and its preparation method and application
|
|
CN109010249A
|
|
Injection dabigatran etcxilate pharmaceutical composition and its preparation method and application
|
|
CN107739385A
|
|
A kind of preparation method of dabigatran cyclic derivatives
|
|
CN107739384A
|
|
A kind of preparation method of dabigatran cyclic derivatives
|
|
CN107739383A
|
|
A kind of preparation method of dabigatran cyclic derivatives
|
|
CN106511262A
|
|
Posaconazole oral solution and preparation method thereof
|
|
CN106333925A
|
|
Posaconazole liquid suspension and preparation method thereof
|
|
CN105985252A
|
|
Aspartic acid-ornithine crystal IV and preparation method thereof
|
|
CN105622590A
|
|
Posaconazole crystal form VI and preparation method thereof
|
